Advancing T Cell Engagers for Solid Tumors

Our Vision

Context is dedicated to developing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors.

Our Pipeline

Context Therapeutics is building an innovative portfolio of clinical-stage T cell engaging bispecific therapeutics. Product candidates include:

  • CTIM-76: Claudin 6 (CLDN6) x CD3 bispecific antibody

  • CT-95: Mesothelin (MSLN) x CD3 bispecific antibody

  • CT-202: Nectin-4 x CD3 bispecific antibody